Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Glenn S Tillotson

Showing results (1-10 of 63) with videos related to

Pageof 7
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 25, 2010
Development of new antibacterials: a laudable aim, but what is the value?Glenn S Tillotson
Expert Review of Anti-Infective Therapy|October 14, 2008
Where does novel antibiotics R&D stand among other pharmaceutical products: an industrial perspective?Glenn S Tillotson
The Lancet. Infectious Diseases|April 28, 2017
Keeping the faith-reporting on antimicrobial resistance in an era of fake newsGlenn S Tillotson
Chest|May 10, 2016
COUNTERPOINT: Do Randomized Controlled Trials Ignore Needed Patient Populations? NoGlenn S Tillotson
The Lancet. Infectious Diseases|October 27, 2012
GAIN Act legislation: is it enough?Glenn S Tillotson
Expert Review of Clinical Pharmacology|January 14, 2014
Antibiotic resistance: the challenge from an industry perspectiveGlenn S Tillotson
Postgraduate Medicine|May 6, 2016
Where in the world? The role of geography in antibiotic resistance and the potential impact in pulmonary infectionsGlenn S Tillotson
The Lancet. Infectious Diseases|June 12, 2020
A new dawn for the management of influenza?Glenn S Tillotson
The Lancet. Infectious Diseases|April 12, 2002
Natural might not be healthierGlenn S Tillotson
Expert Review of Anti-Infective Therapy|July 30, 2008
Role of gemifloxacin in community-acquired pneumoniaGlenn S Tillotson
Pageof 7

Showing results (1-10 of 63) with videos related to

Sort By:
Pageof 7
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 25, 2010
Development of new antibacterials: a laudable aim, but what is the value?Glenn S Tillotson
Expert Review of Anti-Infective Therapy|October 14, 2008
Where does novel antibiotics R&D stand among other pharmaceutical products: an industrial perspective?Glenn S Tillotson
The Lancet. Infectious Diseases|April 28, 2017
Keeping the faith-reporting on antimicrobial resistance in an era of fake newsGlenn S Tillotson
Chest|May 10, 2016
COUNTERPOINT: Do Randomized Controlled Trials Ignore Needed Patient Populations? NoGlenn S Tillotson
The Lancet. Infectious Diseases|October 27, 2012
GAIN Act legislation: is it enough?Glenn S Tillotson
Expert Review of Clinical Pharmacology|January 14, 2014
Antibiotic resistance: the challenge from an industry perspectiveGlenn S Tillotson
Postgraduate Medicine|May 6, 2016
Where in the world? The role of geography in antibiotic resistance and the potential impact in pulmonary infectionsGlenn S Tillotson
The Lancet. Infectious Diseases|June 12, 2020
A new dawn for the management of influenza?Glenn S Tillotson
The Lancet. Infectious Diseases|April 12, 2002
Natural might not be healthierGlenn S Tillotson
Expert Review of Anti-Infective Therapy|July 30, 2008
Role of gemifloxacin in community-acquired pneumoniaGlenn S Tillotson
Pageof 7